Sylics was acquired by InnoSer. To see what’s new, read below or use the navigation bar to find the information you need.

    Tau Seeding Models

    Recapitulate the key structural features and spreading of tau pathology found in the brain of Alzheimer’s disease and other tauopathy patients

    Home » Neurology Research Models and Services  » Alzheimer’s models and services » Alzheimer’s models – Tau Seeding Models
    The histopathological hallmarks of Alzheimer’s disease (AD) are extracellular plaques composed of amyloid beta (Aβ) and intracellular inclusions of the protein Tau (neurofibrillary tangles). Tau pathology in AD and other Tauopathy patients (frontotemporal dementia (FTD), frontotemporal lobar degeneration, corticobasal degeneration, progressive supranuclear palsy, Pick’s disease) is strongly associated with neurodegeneration and clinical symptoms. 

    Injection of brain extract from Tauopathy patients in the mouse brain locally induces Tau pathology. The induced Tau pathology strongly mimics the lesions found in human AD and other Tauopathy patients and accordingly spreads to other brain regions.  

    InnoSer has extensive preclinical research experience with Tau seeding using AD patient-derived brain extracts in different Tau transgenic mice. Brain extracts from other Tauopathies can also be used, mimicking the unique features of Tau pathology in these diseases. The choice of the patient brain source depends on the Tauopathy of interest.  

    Take advantage of InnoSer’s preclinical research expertise in modelling Tau pathology, flexibility, and collaborative approach for your research. Our in-house neurology experts have long-standing experience with modelling Tau pathology in vivo and are happy to help guide your decision on study design fit for your current research goals.  

    Tau seeding models key characteristics:

    • Human brain-derived or recombinant Tau aggregates 
    • Injections in transgenic or humanized Tau mice
    • Tau seeding in amyloid models allows simultaneous modelling of both AD pathologies.
    • Injection of Tau seeds in transgenic Tau mice with FTD-related mutations leads to rapid and aggressive induction and propagation of Tau pathology. 

    Find the right model for you.

    Compare our model capabilities and discover which of our neurology platforms suits your research needs

    Belgian based preclinical neurology CRO mouse models

    Key readouts

    Test the efficacy of your treatments in the following battery of cognitive behavioural tests:

    Test the efficacy of your treatments with the following biological readouts:

    • MSD: Plasma, CSF and brain (phosphorylated Tau, cytokines, NF-L)
    • (Digital) histopathology 
    • Immunohistochemistry (e.g., pTau, neuroinflammation.)

    Related Alzheimer’s disease model options

    Neurology Platform Overview

    Highly relevant neurology models to facilitate preclinical drug development

    Transgenic Tau Models

    InnoSer offers unique research services with several different transgenic tau models, which recapitulate the Tau neurofibrillary tangle pathology of AD.

    Transgenic Amyloid Models

    InnoSer offers preclinical research services with several different transgenic amyloid models, which recapitulate the plaque pathology of AD.

    AAALAC Accreditation

    InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.

    AAALAC logo

    Animal Welfare

    The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.

    Need more information?

    If you have any questions about how we can help accelerate your research,

    then let us know